drugset / Trial / NCT07169825
Evaluation of Targeted Radionuclide Therapy of Lu-177 PSMA in Patients With Compromised Renal and/or Bone Marrow Function
NaSingle-groupOpen-labelOther
Summary
To determine the dose of Pluvicto therapy absorbed in the tumors and organs of patients whose kidneys and/or bone marrow are not working properly.
Timeline
- Start
- 2026-03-30
- Primary completion
- 2026-09-01
- Completion
- 2028-09-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | 177Lu-DOTATATE | Peptide | — | Intravenous |
Indications
No indication recorded.